Rivaroxaban NDC 72603-890

NDC codes

FDA NDC Directory

Product NDC (as listed)72603-890Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72603-0890Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72603-890-01	72603089001	60 TABLET, FILM COATED in 1 BOTTLE (72603-890-01)Marketed from Jun 4, 2026
72603-890-02	72603089002	180 TABLET, FILM COATED in 1 BOTTLE (72603-890-02)Marketed from Jun 4, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Rivaroxaban
Generic name (nonproprietary): rivaroxaban
Active ingredients: Rivaroxaban — 2.5 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: NorthStar RxLLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 213114
Marketing start: Jun 4, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Factor Xa Inhibitors (Mechanism)
Identifiers: Product ID 72603-890_88246a0e-befe-4dc6-81e1-4b7adc266db2SPL ID 88246a0e-befe-4dc6-81e1-4b7adc266db2SPL set ID 88246a0e-befe-4dc6-81e1-4b7adc266db2RxCUI 2059015UNII 9NDF7JZ4M3
Pharmacologic class: Factor Xa Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472603089001 followed by a unit qualifier and the quantity

Package 72603-0890-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 4, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Rivaroxaban tablets are a factor Xa inhibitor indicated: • to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) • to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) 1.7 Reduction of Risk of Major Cardiovascular Events in Patients with Coronary Artery Disease (CAD) Rivaroxaban tablets, in combination with aspirin, is indicated to reduce the risk of major cardiovascular events (cardiovascular death, myocardial infarction, and stroke) in adult patients with coronary artery disease. 1.8 Reduction…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 213114

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 213114
Product	Strength	Form · route	Labeler	Product NDC
Rivaroxaban	Rivaroxaban 2.5 mg/1	Tablet, Film coatedOral	Macleods Pharmaceuticals Limited	33342-488